FIRST AMENDMENT TOExclusive License Agreement • November 10th, 2016 • ChromaDex Corp. • Medicinal chemicals & botanical products
THIS FIRSTAMENDMENT (“Amendment”) is effective as of June 13, 2016, by and between the TRUSTEES OF DARTMOUTH COLLEGE, a non-profit educational and research institution existing under the laws of the State of New Hampshire (hereinafter “Dartmouth”) and CHROMADEX INC. having its principal place of business at 10005 Muirlands Blvd., Suite G, Irvine, California 92618; hereinafter called Company. (hereinafter “Company”).
LICENSE AGREEMENTLicense Agreement • November 10th, 2016 • ChromaDex Corp. • Medicinal chemicals & botanical products • New York
THIS LICENSE AGREEMENT is made as of this 1st Day of August 2013 (“Execution Date”) by and between the GREEN MOLECULAR S.L., a Spanish corporation with a principal address at Parc Cientific Universidad de Valencia, Polígono La Coma s/n, 46980 Paterna, Valencia, Spain (“GM”) and Chromadex, Inc. , a corporation organized and existing under the laws of California with a principal address 10005 Muirlands Bvld Suite G, Irvine , California 92618 (“CHROMADEX”)
SECOND ADDENDUM TO THE NIAGEN® SUPPLY AGREEMENT BETWEENChromaDex Corp. • November 10th, 2016 • Medicinal chemicals & botanical products
This Second Addendum (the “Second Addendum”), effective and binding as of the last date of signing of this Second Addendum (“Second Addendum Effective Date”), is attached to and forms part of the SUPPLY AGREEMENT (the “Agreement”) dated August 28, 2015 and the First Addendum dated September 30, 2015, made by and between ChromaDex, Inc., a California corporation, having a principal place of business at 10005 Muirlands Blvd, Suite G, Irvine, CA 92618 (“Seller”) and Nectar7 LLC, a Delaware limited liability company, with principal offices located at 12526 High Bluff Drive, Suite 210, San Diego, CA 92130 (“Buyer”). To the extent that any of the terms or conditions contained in this Second Addendum may contradict or conflict with any of the terms or conditions of the Agreement or the First Addendum, it is expressly understood and agreed that the terms of this Second Addendum shall take precedence and supersede the Agreement and First Addendum.
CHROMADEX, INC. - DARTMOUTH EXCLUSIVE LICENSE AGREEMENTDartmouth Exclusive License Agreement • November 10th, 2016 • ChromaDex Corp. • Medicinal chemicals & botanical products • New York
TRUSTEES OF DARTMOUTH COLLEGE, a non-profit educational and research institution existing under the laws of the State of New Hampshire, and being located at Hanover, New Hampshire 03755, hereinafter called Dartmouth,
AMENDMENT #1 TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • November 10th, 2016 • ChromaDex Corp. • Medicinal chemicals & botanical products
This Amendment #1 (“First Amendment”) is made and entered into on December 15, 2015 (“First Amendment Effective Date”) by and between The Washington University, a corporation established by special act of the Missouri General Assembly approved February 22, 1853 and acts amendatory thereto, having its principal offices at One Brookings Drive, St. Louis, Missouri 63130 (hereinafter referred to as “WU”) and Chromadex, Inc., a corporation of the State of California, having a place of business at 10005 Muirlands Blvd., Suite G, Irvine, CA 92618 (hereinafter referred to as “Licensee”), each a “Party” or collectively the “Parties” of this Agreement.
EXCLUSIVE LICENSE AGREEMENT PREAMBLEExclusive License Agreement • November 10th, 2016 • ChromaDex Corp. • Medicinal chemicals & botanical products • Missouri
This Agreement is made and entered into, effective as of March 4, 2013, (“Effective Date”) by and between: Washington University, a corporation established by special act of the Missouri General Assembly approved February 22, 1853 and acts amendatory thereto, having its principal offices at One Brookings Drive, St. Louis, Missouri 63130 (hereinafter referred to as "WU"); and Chromadex a corporation organized and existing under the laws of the State of California, having its principal offices at 10005 Muirlands Blvd. Suite G Irvine CA 92618 (hereinafter referred to as "Licensee") and the following correspondence addresses:
Nicotinamide Riboside Supply Agreement between Thorne Research, Inc. & Chromadex, Inc. Nicotinamide Riboside-Choline and/or BetaineChromaDex Corp. • November 10th, 2016 • Medicinal chemicals & botanical products
Seller Chromadex, Inc. Buyer Thorne Research, Inc. Product Nicotinamide Riboside Chloride (Product Specification attached hereto) Term As defined by the NIAGEN® SUPPLY AGREEMENT, dated July 9, 2013 (“Original Agreement”) Intent 1) To add Choline and/or Betaine and/or dimethylglycine (DMG) to the Original Agreement (hereinafter the NR-Choline-Betaine-DMG Combination Product) 2) To permit Buyer the sole rights to the Combination of Nicotinamide Riboside (NR) with Choline and/or Betaine and/or DMG (all forms) 3) To permit Buyer the right to engage in the research, advertising, promotion, manufacturing, packaging, shipment, distribution, use, offer for sale, and sale of the NR-Choline-Betaine-DMG Combination Product or of Derivatives of the NR-Choline-Betaine-DMG Combination Product 4) Derivatives of the NR-Choline-Betaine-DMG Combination Product are defined as any product that contains the NR-Choline-Betaine-DMG Combination in combination with any other ingredient(s)
FIRST AMENDMENT TO THE LICENCE AGREEMENTLicence Agreement • November 10th, 2016 • ChromaDex Corp. • Medicinal chemicals & botanical products
THIS FIRST AMENDMENT to the LICENSE AGREEMENT with an Effective Date of October 15, 2014 is made as of this July 6, 2015 (“Effective Date of the Amendment”), by and between the UNIVERSITY OF MISSISSIPPI, and CHROMADEX, INC. concerning a blue green algae technology.
SECOND AMENDMENT TO THE LICENSE AGREEMENT BETWEEN THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AND CHROMADEX INC.ChromaDex Corp. • November 10th, 2016 • Medicinal chemicals & botanical products
This second amendment (the “Second Amendment”), dated December 31st, 2015 (the “Effective Date”), is made by and between The Regents of the University of California (“The Regents”), a California corporation having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through the offices of The University of California, Irvine located at 5171 California Ave, Suite 150 CA 92697-7700 and ChromaDex Inc. (“Licensee”) having a principal place of business at 10005 Muirlands Blvd, Suite G, Irvine, CA 92618 and amends the license agreement with Licensee, dated September 8, 2011 with UC Agreement Control Number 2012-04-0120 (the “License Agreement”).
Second Addendum to Nicotinamide Riboside Supply Agreement between Thorne Research, Inc. & ChromaDex, Inc. Nicotinamide Riboside-Choline and/or BetaineChromaDex Corp. • November 10th, 2016 • Medicinal chemicals & botanical products
Seller ChromaDex, Inc. Buyer Thorne Research, Inc. Effective Date September 14, 2016 Intent of Second Addendum 1) To extend the Term of the NIAGEN® SUPPLY AGREEMENT, dated July 9, 2013 (“Original Agreement”) between the parties. 2) To amend in the entirety, the Territory, the Exclusivity in the Territory, and the Exclusivity Requirements in the Original Agreement and in the Addendum to the Nicotinamide Riboside Supply Agreement, dated July 24, 2015 (“Addendum”). Term October 1, 2016 through December 31, 2018 Territory and Exclusivity in the Territory (amended) 1) Thorne retains exclusivity for stand-alone NR in the Licensed Health Care Professionals Channel in the United States only. 2) Thorne retains exclusive rights to the combination of Nicotinamide Riboside (NR) with Choline and/or Betaine and/or DMG (all forms) (“Combination Product”) in all channels, in the United States and Canada, with right of first refusal for other countries. 3) Thorne obtains exclusive rights to the combina
